Thank you, Shiraz. As Michael indicated, we've continued to shift our portfolio towards specialty finance strategies because of their more attractive risk-adjusted returns in today's market. Our specialty finance strategies offer higher pricing than sponsor finance loans and greater downside protection through their underlying collateral, which includes accounts receivable, finished goods inventory, commercial loan portfolios, essential use equipment as well as intellectual property. In most cases, the assets are governed by dynamic borrowing base frameworks, which enable real-time monitoring of the underlying asset performance. Moreover, they provide levers for us to manage our exposure, including eligibility tightening, advanced rate adjustments and cash dominion. This downside protection is critical in periods of economic uncertainty like today. Importantly, we are fortunate to have the infrastructure across our investment strategies that enables us to capitalize on this attractive opportunity set in collateral-based lending strategies. Now let me turn to the portfolio. At quarter end and on a fair value basis, comprehensive investment portfolio consisted of approximately $3.2 billion with an average exposure of $3.5 million. Measured at fair value of 98.3% of the comprehensive portfolio consisted of senior secured loans with approximately 96% invested in first lien loans including our investment in the SSLP and only 0.2% was invested in second lien cash flow loans with the remaining 2.2% invested in second lien asset-based loans. At quarter end, our weighted average yield on the comprehensive portfolio was 12.2%, consistent with the first quarter. We attribute this consistency to the heavy weighting towards specialty finance in our first half of 2025 originations. Based on our quantitative risk assessment scale, the portfolio currently has one of the strongest credit profiles in SLRC's history. At quarter end, the weighted average investment risk rating was under 2 based on our 1 to 4 risk rating scale, with 1 representing the least amount of risk. Just under 98% of the portfolio is rated 2 or higher. More over 99.5% of the portfolio on a cost basis and 99.7% on a fair value basis was performing with only 1 investment on nonaccrual. Now let me touch on each of our 4 investment verticals. I'll start with asset-based lending. At quarter end, the ABL portfolio totaled over $1.3 billion across 259 borrowers, representing approximately 42% of our comprehensive portfolio. Regional domestic banks have continued to adjust their business models and are retreating from the ABL market, creating attractive opportunity for SLRs ABL team. Under tighter credit regulations, regional banks' asset-based loans to nonrated companies are bumping into higher risk capital charges, which makes these business lines economically less attractive to the banks. SLR is positioned to collaborate with these banks who are shifting their ABL strategies in reaction to these capital challenges. For the second quarter, we originated $373 million of new ABL investments and had repayments of just under $150 million. To give you a flavor of a couple of transactions in the quarter. We closed on a $125 million first lien ABL borrowing base-driven credit facility to a manufacturer and supplier of products for the North American agricultural and food system. Proceeds from the loan will be used to refinance their existing loans. The highly structured ABL facility provides an advance against liquidation value of both the company's receivables and the inventory. In another ABL investment, we arranged a working capital solution via a $35 million commitment to a senior secured ABL credit facility for a leading regional jewelry retailer. Our investment repaid an existing credit facility and is structured with a first priority security interest in all assets, including the jewelry. In the second quarter, the weighted average asset level yield of our ABL portfolio was 13.4% compared to 13.8% in the first quarter. We continue to see opportunities to provide ABL facilities to traditional cash flow borrowers who are experiencing liquidity pressures. This capability allows us to continue to be a value-added partner to our sponsors, clients during times when the cash flow opportunity set carries a less favorable risk reward profile. These are highly structured ABL facilities, which can achieve higher advance rates while maintaining traditional ABL risk parameters and fundamentally expanding the liquidity options for their middle market borrowers. A good example of this is the recent $75 million investment by our platform in an ABL facility to a sponsor-owned premium pet food manufacturer against the liquidation value of their receivables and finished goods inventory. Utility was used to repay their existing loan and provide liquidity for ongoing working capital needs. With the increased demand for our ABL solutions, we've continued to add personnel and evaluate further ways to expand and support our ABL franchise. It's important to note that this increased demand for ABL solutions is very different than the ever-present headlines of an increasing supply of asset-based finance strategies among some of our peer alternative investment managers. The recent headlines reflect more of an expansion of the opportunity set in asset-based finance or asset-based securitizations which includes the financing of pools of consumer assets such as credit card receivables, student loans and residential mortgages, just to name a few. While these pools of financial assets are large and present scaled opportunities for diversified asset managers to distribute in size, it remains an area of very different than SLR's focus on direct lending to individual companies backed by their working capital assets, including receivables and inventory. We continue to focus on the commercial borrower and believe that our specialized focus in ABL as meaningful barriers to entry. Now let me touch on equipment finance. At quarter end, this portfolio totaled just over $1 billion, representing just under 33% of our comprehensive portfolio and was diversified across 630 borrowers. The credit profile was unchanged and stable quarter-over-quarter. During the second quarter, we originated just over $140 million of new assets with the majority of this coming from our business that provides leases to investment- grade corporate borrowers. We had repayments of approximately $170 million. The weighted average asset level yield for this asset class was 11.6%, consistent with the first quarter. Our investment pipeline has expanded and we're seeing demand from our borrowers to extend their existing leases on equipment rather than buying new equipment at higher tariff-adjusted prices. Now let me turn to Life Sciences. Our life science portfolio totaled approximately $215 million across 9 borrowers. 75% of the portfolio is invested in companies that have over 12 months of cash runway. Additionally, 8 out of 9 of these companies have revenues with at least 1 product in commercialization stage, which significantly derisks our life science investments. Life Science debt investments represented just under 7% of the comprehensive portfolio and contributed 12% of our gross investment income for the quarter. During the second quarter, the team funded approximately $30 million of new investments, including 2 incremental investments to existing borrowers and had just $1 million of contractual amortization repayments. Leading the originations for Life Sciences in the second quarter was a partial funding associated with a new $400 million debt facility for Cogent, a publicly traded biotech company that includes tranches subject to clinical and operating milestones for future draws under our facility. We believe our life science team's long-standing relationships and expertise in the sector ultimately, let SLR winning this business or a groundbreaking company of one of the largest commitments for life sciences in SLR's history. At quarter end, the weighted average yield on the first lien portfolio was 13.1%, inclusive of potential success fees, but excluding warrants. We are seeing signs of recovery in the life science sector. However, the recent cuts at the FDA and NIH, evolving public policy and continuing valuation challenges remain headwinds for the sector. Now more than ever, extensive industry expertise is required to successfully navigate the investment opportunity set. We are fortunate to have one of the most seasoned teams in life science lending and while they continue to remain extremely cautious, the pipeline of opportunities is increasing. Finally, let me touch on Sponsor Finance. In our sponsor finance business, we originate first lien senior secured loans to middle market companies in noncyclical industries, such as health care, business services and financial services. This has helped us mitigate the impact on our portfolio from cyclical factors as well as tariffs. At quarter end, the sponsor cash portfolio was just under $550 million across 33 borrowers, including loans in our SSLP. With approximately 99% of the cash flow portfolio invested in first lien loans, we believe we are well positioned to withstand either tariff or economic headwinds. Our borrowers have a weighted average EBITDA of approximately $90 million and carry low LTVs of under 44%. In Sponsor Finance, the average EBITDA and revenue growth continues to be in the mid-single digits year-over-year for our portfolio companies. Overall, they have successfully managed the transition to an environment with higher cost of capital as well as input prices. Weighted average interest coverage on our sponsor finance book is 1.8x. Additionally, approximately $500,000 of our second quarter gross investment income is in the form of capitalized PIK and cash flow borrowers, resulting from amendments. During the quarter, we made investments of $24 million in first lien cash flow loans and experienced repayments of just under $70 million. As Michael mentioned, sponsor finance deal flow continues to be muted due to the lower M&A volume, and we are selectively letting investments go in connection with refinancings if their new risk return profiles do not meet our investment criteria. Our specialty finance strategies enable us to be more selective in cash flow lending during periods of increased competition. At quarter end, the weighted average yield on our cash flow portfolio was 10.3% down from 10.4% in the first quarter. Lastly, let me touch on our SSLP. During the second quarter, we earned total income of $1.1 million from the SSLP representing a 9.3% annualized yield. During the quarter, we made $32 million of new investments and had repayments of $14 million. The investment portfolio began the quarter at just under 1x leverage and ended at 1.15x levered. We expect to continue to rebuild this portfolio opportunistically. At quarter end, the SSLP had capacity approximately $70 million. Now let me turn it back to Michael.